| 9.76 0.72 (7.96%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.25 | 1-year : | 14.31 |
| Resists | First : | 10.49 | Second : | 12.25 |
| Pivot price | 9.5 |
|||
| Supports | First : | 8.5 |
Second : | 7.26 |
| MAs | MA(5) : | 9.4 |
MA(20) : | 9.48  |
| MA(100) : | 8.26 |
MA(250) : | 5.47 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 60.1 |
D(3) : | 55.2 |
| RSI | RSI(14): 54.7 |
|||
| 52-week | High : | 14.52 | Low : | 2.22 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ARTV ] has closed below upper band by 25.8%. Bollinger Bands are 72.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 10.12 - 10.17 | 10.17 - 10.22 |
| Low: | 8.64 - 8.69 | 8.69 - 8.74 |
| Close: | 9.67 - 9.76 | 9.76 - 9.84 |
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
Fri, 17 Jul 2026
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Wed, 08 Jul 2026
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Wed, 08 Jul 2026
Should I buy Artiva Biotherapeutics, Inc. (ARTV) - Zacks Investment Research
Mon, 29 Jun 2026
Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) added to Russell 2000 Growth Benchmark - marketscreener.com
Tue, 23 Jun 2026
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewswire
Thu, 21 May 2026
Have Insiders Sold Artiva Biotherapeutics Shares Recently? - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 14.1 (%) |
| Held by Institutions | 51.5 (%) |
| Shares Short | 1,340 (K) |
| Shares Short P.Month | 1,030 (K) |
| EPS | -3.55 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.54 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -38.8 % |
| Return on Equity (ttm) | -67.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.85 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -78 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -2.75 |
| PEG Ratio | 0 |
| Price to Book value | 2.74 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|